Skip to main content

Table 3 Categorical changes in weight and laboratory values at endpoint

From: Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia

  

OLZ LAI 150 n/N (%)

OLZ LAI 405 n/N (%)

OLZ LAI 300 n/N (%)

Cochran-Armitage p-value

Weight

≥7% gain

17/140 (12.14)

34/315 (10.79)

24/140 (17.14)

.127

 

≥7% loss

9/140 (6.43)

13/315 (4.13)

7/140 (5.00)

.720

Fasting glucose

Normal to borderline

14/75 (18.67)

37/176 (21.02)

25/89 (28.09)

.121

 

Normal/borderline to high

5/106 (4.72)

6/244 (2.46)

4/108 (3.70)

.855

 

Normal to high

1/75 (1.33)

2/176 (1.14)

0/89 (0)

.311

 

Borderline to high

4/31 (12.90)

4/68 (5.88)

4/19 (21.05)

.320

Fasting HDL

Normal to low

8/58 (13.79)

26/133 (19.55)

19/62 (30.65)

.019

Fasting LDL

Normal to borderline

6/26 (23.08)

15/66 (22.73)

5/18 (27.78)

.702

 

Normal to high

0/26 (0)

0/66 (0)

0/18 (0)

-------

 

Borderline to high

6/53 (11.32)

14/129 (10.85)

9/73 (12.33)

.804

Fasting total cholesterol

Normal to borderline

9/48 (18.75)

15/133 (11.28)

10/51 (19.61)

.607

 

Normal to high

0/48 (0)

2/133 (1.50)

2/51 (3.92)

.127

 

Borderline to high

4/34 (11.76)

13/65 (20.00)

5/35 (14.29)

.959

Fasting triglycerides

Normal to borderline

13/62 (20.97)

17/133 (12.78)

9/53 (16.98)

.713

 

Normal to high

2/62 (3.23)

8/133 (6.02)

10/53 (18.87)

.001

 

Normal to extremely high

0/62 (0)

0/133 (0)

1/53 (1.89)

.082

 

Borderline to high

3/14 (21.43)

11/38 (28.95)

3/18 (16.67)

.556

 

Borderline to extremely high

0/14 (0)

0/38 (0)

1/18 (5.56)

.114

Prolactin

Normal to high (females)

2/17 (11.76)

9/42 (21.43)

7/21 (33.33)

.112

 

Normal to high (males)

4/49 (8.16)

16/116 (13.79)

7/52 (13.46)

.523

  1. Abbreviations: OLZ LAI = olanzapine long-acting injection; OLZ LAI 150 = group receiving low-dose olanzapine LAI, 150 mg every 2 weeks, approximate oral equivalent 10 mg/day (N = 140); OLZ LAI 405 = group receiving medium-dose olanzapine LAI, 405 mg every 4 weeks, approximate oral equivalent 15 mg/day (N = 318); and OLZ LAI 300 = group receiving high-dose olanzapine LAI, 300 mg every 2 weeks, approximate oral equivalent 20 mg/day (N = 141); HDL = high-density lipoprotein; LDL = low-density lipoprotein.